Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 18/20 | 0.47 |
| ▸ | CTSB | P07858 | 5/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20974863 | 0.95 | YTHDC1 (0.46) | CTSLCTSBYTHDC1CHKA | |
| SCHEMBL19575525 | 0.92 | YTHDC1 (0.51) | CTSLCTSBYTHDC1CHKA | |
| SCHEMBL20974975 | 0.92 | CHKA (0.43) | CTSLCTSBYTHDC1CHKA | |
| SCHEMBL20974433 | 0.92 | PADI3 (0.47) | CTSLCTSBYTHDC1CHKA | |
| SCHEMBL19575538 | 0.89 | CHKA (0.42) | CTSLCTSBYTHDC1CHKA | |
| SCHEMBL19575483 | 0.89 | CHKA (0.43) | CTSLCTSBYTHDC1CHKA | |
| SCHEMBL19575570 | 0.89 | CTSL (0.42) | CTSLCTSB | |
| SCHEMBL20972934 | 0.88 | CTSL (0.47) | CTSLCTSBCHKA | |
| SCHEMBL20975222 | 0.86 | CTSL (0.48) | CTSLCTSBYTHDC1CHKA | |
| SCHEMBL19575672 | 0.86 | CHKA (0.46) | CTSLYTHDC1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | CTSL 4183/4885CTSB 4090/4885YTHDC1 2334/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | CTSL 4183/4885CTSB 4090/4885YTHDC1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.